No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FBIO Fortress Biotech
- 1.7900
- -0.1100-5.79%
Close Jun 18 16:00 ET
- 1.8001
- +0.0101+0.56%
Post 18:38 ET
35.65MMarket Cap-296P/E (TTM)
1.9600High1.7800Low273.26KVolume1.9000Open1.9000Pre Close516.22KTurnover1.82%Turnover RatioLossP/E (Static)19.92MShares10.350052wk High1.55P/B26.92MFloat Cap1.240052wk Low--Dividend TTM15.04MShs Float190.5000Historical High--Div YieldTTM9.47%Amplitude1.2400Historical Low1.8890Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Why Is Penny Stock Mustang Bio Trading Over 190% On Monday?
Penny stock Mustang Bio Inc (NASDAQ:MBIO) shares are trading higher on a strong session volume of 90 million versus an average volume of 3.17 million, as per data from Benzinga Pro.Mustang was founded
Express News | Mustang Bio Inc: Overall Response Rate of 90% in Cohort With Durable Responses Observed; One Patient Remains in Complete Remission at 31 Months
Express News | Mustang Bio Announces Favorable Efficacy and Safety Data From Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous CAR-T Therapy
Fortress Announces £750 Million Forward Flow Agreement to Support the Continued Growth of Tabeo, the UK's Largest Provider of Retail Finance for Primary Care Providers
NEW YORK & DALLAS--(BUSINESS WIRE)--Fortress today announced the completion of a £750 million forward flow agreement with Tabeo, the largest provider of retail finance for primary care providers in th
Fortress Biotech Shareholders Endorse Governance and Incentives
Fortress Biotech(FBIO.US) 10% Shareholder Buys US$17,589 in Common Stock
$Fortress Biotech(FBIO.US)$ 10% Shareholder ROSENWALD LINDSAY A MD purchased 10,000 shares of common stock on May 16, 2024 at an average price of $1.7589 for a total value of $17,589.Source: Announcem
Comments
$Fortress Biotech(FBIO.US$ Reuters· just
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024
Fortress Biotech Inc: FDA Accepted Nda Filing for Dfd-29 to Treat Inflammatory Lesions & Erythema of Rosacea in Adults; Pdufa Goal Date of Nov 4, 2024
2
$Fortress Biotech(FBIO.US$ even after good resilt thus share is going down. holding since last 3 months now.
The low P/S ratio is likely due to investors' concerns about the company's poor revenue performance and underwhelming growth outlook. The company will need a significant change in fortune to justify a higher P/S ratio in the future.
$Fortress Biotech(FBIO.US$ $Mustang Bio(MBIO.US$ City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
4 MINUTES AGO, 5:00 AM EST
VIA BUSINESSWIRE
• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...
4 MINUTES AGO, 5:00 AM EST
VIA BUSINESSWIRE
• Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced complete response
• Nature Medicine paper highlights delivery of CAR T cell therapy directly to the brain, a technique Ci...
2
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg